Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype
Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
DRUG: Chidamide combined with CHOP|DRUG: Chidamide
Complete remission rate, Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria., Up to 18 weeks
Objective response rate, Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria., Up to 18 weeks|Partial remission rate, Partial remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria., Up to 18 weeks|Progression-free survival（PFS）, To investigate the preliminary antitumor efficacy, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|Overall survival, To investigate the preliminary antitumor efficacy, From date of randomization until the date of death from any cause, assessed up to 24 months|Recurrence free survival, To investigate the preliminary antitumor efficacy, From date of randomization until the date ofthe occurrence of relapse or last visit, assessed up to 24 months|Number of participants with adverse events (AE) and severe adverse events (SAE) as assessed by CTCAE v5.0, To identify the incidence of AE and SAE, Up to 18 weeks
This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype